Antwerp, Belgium–(BUSINESS WIRE)–Regulatory news:
Azelis (Brussels: AZE), one of the world’s leading providers of innovation services to the specialty chemicals and food ingredients industry, is pleased to announce a new agreement with Roquette for the distribution of its of cellulose-based pharmaceuticals in India.
Highlights and Rationale
This collaboration expands Azelis India’s presence in the pharmaceutical excipient market segment.
This new mandate builds on and strengthens Azelis and Roquette’s global strategic partnership that spans multiple regions and industries.
This agreement is in line with Azelis’ commitment to grow organically with strategic partners and expand its presence in developing and emerging economies such as India.
Roquette is a world leader in plant-based ingredients, a pioneer in plant-based proteins and a leading supplier of pharmaceutical excipients. Roquette’s products, including its plant-based excipients, combined with Azelis’ dedicated application labs and formulation expertise, will enable both companies to provide their customers and partners with tailored innovative solutions.
Through this collaboration, Azelis India expands its comprehensive product portfolio with the inclusion of Roquette’s Microcrystalline Cellulose (MCC) and Croscarmellose Sodium (CCS) products. The new agreement takes effect immediately.
Azelis’ reputation in the industry, its strong proximity to the customer, its competent sales and technical teams and its expertise in formulation were the decisive factors that led Roquette to enter into this distribution agreement. Azelis has been named Roquette’s distribution partner for the plant care market in Asia-Pacific in 2020and for Food & Health in China in 2021.
Oscar Manuel Cortes Gutierrez, Global Head of Pharmaceutical Distribution Management at Roquette comments:
“Azelis has been our preferred partner for many years and we are pleased to continue this pharmaceutical relationship in India, expanding from the Middle East and Africa. We are confident in Azelis’ ability to provide the best services and solutions to our customers, who will now have access to a wider range of customizable solutions for various applications. The synergies resulting from the combination of our ingredients with the technical capabilities of Azelis will lead to more opportunities and growth in the region.
Aparna Khurana, Managing Director of Azelis India, says:
“Adding Roquette’s innovative, plant-based ingredients to our pharmaceutical product offering in India can only be to the benefit of our customers. By strengthening our side value chain, we will be able to offer a more comprehensive and complementary pharmaceutical portfolio, becoming a one-stop shop for customers to formulate solutions that meet unique consumer requirements. We will work to ensure the continued success of our collaboration, leveraging our sales capabilities and market knowledge.
Azelis is a leading global provider of innovation services to the specialty chemicals and food ingredients industry, operating in over 50 countries worldwide and employing approximately 2,800 people. Our knowledgeable teams of industry, market and technical experts are each dedicated to a specific market within life sciences and industrial chemicals. We offer a side value chain of complementary products to over 45,000 customers, supported by ~2,200 primary relationships, generating revenue of €2.22 billion (2020). Azelis Group NV is listed on Euronext Brussels under the symbol AZE.
Through our extensive network of more than 60 application labs, our award-winning staff help develop formulations and provide technical guidance throughout customers’ product development process. We combine a global reach with a local footprint to deliver a reliable, integrated and unique digital service to local customers and attractive business opportunities to constituents. Rated EcoVadis Platinum, Azelis is a leader in sustainability. We believe in building and maintaining strong, honest and transparent relationships with our employees and partners.
Impact through ideas. Innovation through formulation.